Bruce Wendel

Bruce Jeffrey Wendel is Vice Chairman & EVP-Global Corporate Operations at Abraxis Health, Inc. since 2009.
He is Director at Liminal BioSciences Ltd. since 2016.
He is Independent Director at ImmunityBio, Inc. starting in 2025.
He is Chief Strategy Officer at H3 Life Science Corp.
Formerly, Mr. Wendel was Vice Chairman & Chief Executive Officer at Abraxis BioScience, Inc. from 2010 to 2011.
He was Chief Executive Officer at Scientific Protein Laboratories LLC from 2014 to 2015.
He was Chief Executive Officer at Abraxis BioScience LLC.
He was Vice Chairman at GT Biopharma, Inc. from 2020 to 2025.
He was Independent Director at Verastem, Inc. from 2016 to 2021.
He was VP-Corporate Development International Medicines at Bristol Myers Squibb Co. from 1988 to 2002.
He was Vice President-Business Development & Licensing at IVAX LLC.
He was Vice President-Corporate Development at American Pharmaceutical Partners, Inc. from 2004 to 2008.
He was Chief Business Development Officer at Liminal BioSciences, Inc. from 2018 to 2019.
He was President, Chief Financial Officer & Secretary at Stalar 3, Inc. from 2009 to 2010.
He was President, Chief Financial Officer & Secretary at Stalar 4, Inc. from 2009 to 2011.
He was Vice President-Development at Abraxis BioScience, Inc. in 2007.
He was Chief Business Development Officer at ProMetic BioTherapeutics, Inc. from 2018 to 2019.
He was Chief Strategy Officer at Hepalink USA, Inc. from 2012 to 2017.
Education includes undergraduate studies at Cornell University and graduate studies at Georgetown University Law Center.